CM-CSF INSTEAD OF HEMATOLOGICAL SUPPORT DURING HIGH-DOSE CHEMOTHERAPY FOR REFRACTORY MALIGNANT-LYMPHOMA

被引:8
作者
AVILES, A
NAMBO, MJ
TALAVERA, A
ROSAS, A
GARCIA, EL
DIAZMAQUEO, JC
机构
[1] Department of Hematology, Oncology Hospital, National Medical Center Mexico, DF
关键词
MALIGNANT LYMPHOMA; NON-HODGKINS LYMPHOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; BONE MARROW TRANSPLANTATION;
D O I
10.3109/10428199509056839
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with refractory malignant lymphoma (RML) have a poor prognosis when treated with conventional chemotherapy. The use of high-dose chemotherapy has been limited by secondary myelosuppression. We report the use of intensive and short-duration chemotherapy in patients with RML who received granulocyte-macrophage colony-stimulating factor (GM-CSF) instead of hematological support and salvage with bone marrow transplantation or infusion of peripheral blood stem cells. Thirty-one patients with RML were treated with cyclophosphamide: 7 g/m(2), iv on day 1, followed by GM-CSF: 5 mu g/kg/day, subcutaneously until hematological recovery (granulocytes > 1.8 x 10(9)/L) started on day 2. Methotrexate, 5 g/m(2), was also given when the granulocytes and platelets counts were normal, followed by leucovorin rescue. Epirubicin, 180 mg/m(2), iv, was given on day 29 if the granulocyte count was normal, and GM-CSF was started on day 30. Complete response was obtained in 21 out of 31 patients (67%) and partial response in 4 more, thus an overall response was achieved in 80% of the treated patients. Time to treatment failure was 24+ months, and the overall survival was 28+ months. Hematological toxicity grade IV, according to the WHO criteria was observed in all cycles, however hematological recovery was already evident on day 13 +/- 2. Eleven patients developed infection related to the treatment, but no therapy related death was observed. GM-CSF was well tolerated with minimal toxicity. Is evident that GM-CSF can act as hematological support after high-dose chemotherapy in patients who cannot undergo bone marrow transplantation programs. We feel that the use of colony-stimulating factors instead of bone marrow support should be explored in more controlled clinical trials and that high-dose chemotherapy should be considered as primary treatment in patients with poor prognosis non-Hodgkin's lymphoma.
引用
收藏
页码:327 / 330
页数:4
相关论文
共 15 条
[1]  
Aviles A., Garcia E.L., Guzman R., Et al., Estudio comparative) de dosis altas de arabinosido de citosina en combination con cisplatino y dexametasonaen pacientes con linfoma refractario, Rev. Invest. Clin., 43, pp. 146-150, (1991)
[2]  
Bosly A., Coiffier B., Gisselbrecht C., Et al., Bone marrow transplantation prolongs survival after relapse in aggressive lymphoma treated with the LNH-84 regimen, J. Clin. Oncol., 10, pp. 1615-1623, (1991)
[3]  
Lazarus H.M., Crilley P., Ciobanu N., Et al., High dose carmustine, etoposide and cisplatinum and autologous bone marrow transplantation for relapsed and refractory lymphoma, J. Clin. Oncol., 10, pp. 1083-1089, (1991)
[4]  
Dreyfus C., Leblond V., Belanguer C., Et al., Peripheral blood stem cells collection and autografting in high risk lymphomas, Bone Marrow Transplant., 10, pp. 409-413, (1991)
[5]  
Ho A.D., Del Valle F., Engerhard M., Et al., Mitoxantrone/high dose Ara C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin's lymphoma, Cancer, 66, pp. 423-430, (1990)
[6]  
Gianni A.M., Bregni M., Sienna S., Et al., Recombinant human granulocyte-macrophage colony-stimulating factor reduce hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma, J. Clin. Oncol., 8, pp. 768-778, (1990)
[7]  
Yoshida T., Nakamura S., Ohtake S., Et al., Effects of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hodgkin's lymphoma, Cancer, 66, pp. 1904-1909, (1990)
[8]  
Biesma B., Vellenga E., Willemze P.H.B., de Vries E.G.E., Effects of hematopoietic growth factors on chemotherapy induced myelosuppression, Crit. Rev. Oncol. Hematol., 13, pp. 107-134, (1992)
[9]  
Aviles A., Diaz-Maqueo J.C., Torras V., Tratamiento de linfomas malignos refractarios con cisplatino, vinblastina y bleomicina, Rev. Invest. Clin., 42, pp. 99-105, (1990)
[10]  
Aviles A., Diaz-Maqueo J.C., Talavera A., Nambo M.J., Garcia E.L., Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy, Leukemia and Lymphoma, (1994)